Photosensitivity

 

Photosensitivity is a tendency to sunburn easily. Many drugs cause photosensitivity, including some chemotherapy drugs. Protecting your skin from the sun is very important. If you should get a severe sunburn, treatment is aimed at reducing inflammation and relieving pain.

What is photosensitivity?

Photosensitivity is an enhanced skin response to ultraviolet radiation (sunlight). This means that you may sunburn easily. A sunburn that you got within a week before chemotherapy may reappear, or rarely, a sunburn may spread to skin that was not exposed to the sun.

What causes photosensitivity?

There are many drugs that may cause photosensitivity. Chemotherapy drugs commonly associated with photosensitivity include:

  • DTIC-Dome® (dacarbazine)
  • 5-FU (fluorouracil)
  • Methotrexate
  • Velban® (vinblastine)
  • What are the symptoms of photosensitivity?

  • Symptoms of a sunburn include:
  • Redness
  • Inflammation
  • Blistering
  • Weeping
  • Peeling

What is the treatment for photosensitivity?

The treatments for a rash that results from photosensitivity aim to reduce inflammation and relieve pain.

Corticosteroid cream - Steroids work by reducing inflammation. Your doctor may prescribe a corticosteroid cream that you rub on the rash.

Analgesics - These over-the-counter medications can relieve pain associated with a rash. Examples are acetaminophen or aspirin.

What else can I do?

It is very important to protect your skin from the sun by following these tips:

  • Wear long sleeves and long pants.
  • Wear a wide brimmed hat.
  • Wear light, cotton gloves.
  • Use sunscreen on the skin that you cannot cover.
  • Sunblock with physical barrier such as zinc oxide may be necessary for vulnerable areas, such as the hands and nose.

For more information on having sensible fun in the sun, see Sun Sense.

This content was last modified on August 24, 2007 .
Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health